4BIO Capital extends warm congratulations to Professor Dimitri Kullman, member of our Scientific Advisory Board, on his election as Fellow of the Royal Society in recognition of his outstanding contribution to science.
Professor Kullman is a neurologist and neuroscientist who works on how synapses function in health and disease. His laboratory helped to show how neurotransmitters activate different receptor subtypes in and around synapses, and resolved some controversies about the mechanisms of long-term changes in synaptic strength. Genetic and autoimmune disorders of synaptic proteins (‘synaptopathies’) provide unparalleled insights into the mechanisms of a broad range of neurological diseases including epilepsy and migraine. Together with his colleagues, he has used these insights to devise gene therapy strategies that could be used to treat intractable epilepsy.
Professor Kullmann is currently a Professor of Neurology at the UCL Institute of Neurology. He was elected as a Fellow of the Academy of Medical Sciences in 2001, was awarded the Baly medal by the Royal College of Physicians in 2017, and is the editor of Brain.
The Fellowship of the Royal Society is made up of the most eminent scientists, engineers and technologists from or living and working in the UK and the Commonwealth. Past Fellows and Foreign Members have included Isaac Newton, Charles Darwin, Albert Einstein and Stephen Hawking.
Dr Dmitry Kuzmin, 4BIO Capital’s Managing Partner, said: “We’re honoured to work with Professor Kullmann as a member of our Advisory Board, and I’m extremely glad that his groundbreaking research in channelopathies and gene therapy was recognised by the Royal Society””